FOLR1 and ovarian cancer: A study examining the use of a FRα peptide vaccine in combination with the programmed death ligand 1 (PD-L1) inhibitor durvalumab in patients with platinum-resistant ovarian cancer showed increased T cell responses in all 27 patients [45].